CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction

Clinical and Experimental Immunology

Volumn 162, Issue 1, 2010, Pages 116-130

  Nair, P ^a   Melarkode, R ^a   Rajkumar, D ^a   Montero, E ^b  

^a Biocon Limited   (India)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

ALCAM; CD6; human; IL 2; SRCR

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD3 ANTIGEN; CD6 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CLUSTER ANALYSIS; CYTOKINES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956497991     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04235.x     Document Type: Article

References (67)

1. Zhu Y, Chen L. Turning the tide of lymphocyte costimulation. J Immunol 2009 182 : 2557 2558.
2. Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 2009 10 : 333 339.
3. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009 27 : 591 619.
4. van Lier RA, Brouwer M, Rebel VI, van Noesel CJ, Aarden LA. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. Immunology 1989 68 : 45 50.
5. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003 3 : 939 951.
6. Aruffo A, Melnick MB, Linsley PS, Seed B. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J Exp Med 1991 174 : 949 952.
7. Osorio LM, Garcia CA, Jondal M, Chow SC. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cell Immunol 1994 154 : 123 133.
8. Gangemi RM, Swack JA, Gaviria DM, Romain PL. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. J Immunol 1989 143 : 2439 2447.
9. Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006 107 : 3212 3220.
10. Ibanez A, Sarrias MR, Farnos M et al. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006 177 : 1152 1159.
11. Osorio LM, Rottenberg M, Jondal M, Chow SC. Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells. Immunology 1998 93 : 358 365.
12. Ledbetter JA, June CH, Grosmaire LS, Rabinovitch PS. Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci USA 1987 84 : 1384 1388.
13. Bjorndahl JM, Sung SS, Hansen JA, Fu SM. Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. Eur J Immunol 1989 19 : 881 887.
14. Singer NG, Richardson BC, Powers D et al. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 1996 88 : 537 543.
15. Bott CM, Doshi JB, Morimoto C, Romain PL, Fox DA. Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. Int Immunol 1993 5 : 783 792.
16. Bodian DL, Skonier JE, Bowen MA et al. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997 36 : 2637 2641.
17. Whitney GS, Starling GC, Bowen MA, Modrell B, Siadak AW, Aruffo A. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J Biol Chem 1995 270 : 18187 18190.
18. Hassan NJ, Barclay AN, Brown MH. Frontline: optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 2004 34 : 930 940.
19. Cayrol R, Wosik K, Berard JL et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008 9 : 137 145.
20. Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol 2005 5 : 532 545.
21. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004 431 : 527 532.
22. Castro MA, Oliveira MI, Nunes RJ et al. Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse. J Immunol 2007 178 : 4351 4361.
23. Gimferrer I, Calvo M, Mittelbrunn M et al. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004 173 : 2262 2270.
24. Sarrias MR, Farnos M, Mota R et al. CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci USA 2007 104 : 11724 11729.
25. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991 113 : 981 986.
26. Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM. T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 2006 7 : 247 255.
27. Roque-Navarro L, Mateo C, Lombardero J et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003 22 : 245 257.
28. Alonso R, Huerta V, de Leon J et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma 2008 27 : 291 301.
29. IOR-T3 (CD3 human leukocyte differentiation antigen). Hybridoma 1997 16 : 588.
30. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997 3 : 71 81.
31. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981 35 : 269 335.
32. Borisy AA, Elliott PJ, Hurst NW et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003 100 : 7977 7982.
33. Hultin LE, Matud JL, Giorgi JV. Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Cytometry 1998 33 : 123 132.
34. Hodge G, Hodge S, Haslam R et al. Rapid simultaneous measurement of multiple cytokines using 100 microl sample volumes-association with neonatal sepsis. Clin Exp Immunol 2004 137 : 402 407.
35. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003 55 : 61 70.
36. Verma-Gaur J, Rao SN, Taya T, Sadhale P. Genomewide recruitment analysis of Rpb4, a subunit of polymerase II in Saccharomyces cerevisiae, reveals its involvement in transcription elongation. Eukaryot Cell 2008 7 : 1009 1018.
37. Ahmed SA, Gogal RM Jr., Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 1994 170 : 211 224.
38. Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006 5 : 2676 2684.
39. Bromley SK, Burack WR, Johnson KG et al. The immunological synapse. Annu Rev Immunol 2001 19 : 375 396.
40. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 14 : 233 258.
41. King CL, Stupi RJ, Craighead N, June CH, Thyphronitis G. CD28 activation promotes Th2 subset differentiation by human CD4+ cells. Eur J Immunol 1995 25 : 587 595.
42. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007 25 : 619 647.
43. Singer NG, Fox DA, Haqqi TM et al. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 2002 14 : 585 597.
44. Lenschow DJ, Herold KC, Rhee L et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996 5 : 285 293.
45. Osorio LM, Ordonez C, Garcia CA, Jondal M, Chow SC. Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation. Cell Immunol 1995 166 : 44 52.
46. Kunz J, Hall MN. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. Trends Biochem Sci 1993 18 : 334 338.
47. Girard JP, Springer TA. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 1995 2 : 113 123.
48. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997 158 : 658 665.
49. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008 26 : 453 479.
50. Montero E, Alonso L, Perez R, Lage A. Interleukin-2 mastering regulation in cancer and autoimmunity. Ann NY Acad Sci 2007 1107 : 239 250.
51. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 1036.
52. Wee S, Wang WC, Farr AG et al. Characterization of a CD6 ligand(s) expressed on human- and murine-derived cell lines and murine lymphoid tissues. Cell Immunol 1994 158 : 353 364.
53. Singer NG, Mitra R, Lialios F et al. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes. Immunol Lett 1997 58 : 9 14.
54. Joo YS, Singer NG, Endres JL et al. Evidence for the expression of a second CD6 ligand by synovial fibroblasts. Arthritis Rheum 2000 43 : 329 335.
55. Saifullah MK, Fox DA, Sarkar S et al. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues. J Immunol 2004 173 : 6125 6133.
56. Bowen MA, Patel DD, Li X et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995 181 : 2213 2220.
57. Hassan NJ, Simmonds SJ, Clarkson NG et al. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol Cell Biol 2006 26 : 6727 6738.
58. Vera J, Fenutria R, Canadas O et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci USA 2009 106 : 1506 1511.
59. Lenz LL. CD5 sweetens lymphocyte responses. Proc Natl Acad Sci USA 2009 106 : 1303 1304.
60. Bank I, Dardik R, Levy V, Goldstein I, Shoham J. Differential expression and regulation of CD6 on T-cell subsets revealed by monoclonal antibody (MAb) CH11. Hybridoma 2001 20 : 75 84.
61. De Jager PL, Jia X, Wang J et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009 41 : 776 782.
62. Rubio JP, Stankovich J, Field J et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 2008 9 : 624 630.
63. Degre M, Dahl H, Vandvik B. Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurol Scand 1976 53 : 152 160.
64. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986 36 : 777 784.
65. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 1998 92 : 2725 2729.
66. Montero E, Falcon L, Morera Y, Delgado J, Amador JF, Perez R. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity 1999 29 : 155 156.
67. Montero E, Reyes G, Guibert M et al. Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody. Arthritis Res 2002 4 : 114.